Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Cancer Research on Prevention and Treatment》 2012-08
Add to Favorite Get Latest Update

Relationship of CD44~+/CD24~(-/low) with Responsiveness of Breast Cancer to Anthracycline-based Chemotherapy

Zhou Xin1,Wu Chengyi2 1.Department of Breast Surgery,Chongqing Cancer Institute,Chongqing 400030,China;2.Department of Endocrine and Breast Surgery,The First Affiliated Hospital,Chongqing Medical University  
Objective To evaluate the expression of CD44+/CD24-/low and the relationship between CD44+/CD24-/low and the response to anthracyclines-based chemotherapy in patients with breast cancer.Methods A total of 91 patients with breast cancer were treated with anthracycline-based neoadjuvant chemotherapy,and the clinical response to the chemotherapy was obtained after 2 to 4 cycles.Double-staining immunohistochemistry was used to detect the expression of CD44+/CD24-/low in paraffin-embedded tissues of pre-chemotherapy and post-chemotherapy.Data was analyzed via t test and Chi-square test.Results The expression rate of CD44+/CD24-/low phenotype was 39.6%(36/91).The proportions of CD44+/CD24-/lowcells were significantly increased after anthracyclines-based chemotherapy(P=0.028).The positive rate of ER in CD44+/CD24-/low positive group was lower than that in CD44+/CD24-/low negative group(25.0% vs.47.3%,P=0.033).And the expression rate of CD44+/CD24-/low phenotype in triple negative breast cancer was higher than that in non-triple negative breast cancer(61.9% vs.32.9%,P=0.017).There was no significant correlation between CD44+/CD24-/low phenotype and the other clinicopathological parameters,such as age,tumor size,TNM classification,pathological type,histological grade and so on(P0.05).The overall response of CD44+/CD24-/lowpositive group was higher but had no difference compared with CD44+/CD24-/low negative group(75% vs.69.1%,P=0.542),and the rate of pathological complete remission(pCR) in CD44+/CD24-/lowpositive group was higher than that in CD44+/CD24-/lownegative group(38.9% vs.18.2%,P=0.028).Conclusion CD44+/CD24-/lowcells are demonstrated in certain breast cancer,CD44+/CD24-/low phenotype is associated with triple negative breast cancer and the responsiveness of breast cancer to anthracycline-based chemotherapy.CD44+/CD24-/low phenotype may be used as one of the indicators to evaluate the clinical chemotherapeutic response of the patients with breast cancer.
【CateGory Index】: R737.9
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【References】
Chinese Journal Full-text Database 1 Hits
1 Zhang Zong-lin(Linyi City,Shandong Province,People's Hospital,Department of Pharmacy,Linyi 276000,China);Containing Anthracycline Cardiac Toxicity in Breast Cancer Patients with Chemotherapy[J];Chinese Journal of Medicinal Guide;2013-08
【Citations】
Chinese Journal Full-text Database 1 Hits
1 LI Zhi,LIU Chun-ping,HE Yan-li,ZHANG Jing-hui,HUANG Tao (Department of Breast and Thyroid Surgery, Union Hospital,Huazhong University of Science and Technology,Wuhan 430022,China);The expression of multi-drug resistance gene in breast cancer stem cells and its significance[J];Tumor;2008-02
【Co-citations】
Chinese Journal Full-text Database 8 Hits
1 LI Xun,YANG Shun-e,GUAN Ya-qun (Department of Chemotherapy, Affiliated Tumor Hospital Xinjiang Medical University,Urumqi Xinjiang 830011,China);Relation of expression of survivin and BCRP gene in prediction of response to chemotherapy in metastatic breast cancer[J];China Oncology;2009-04
2 YANG Guohua,XUE Fangqing,CHEN Xiaogeng(Department of Oncology Surgery,Fujian Provincal Hospital,Fuzhou 350001,China);Prognostic value of different amounts of cancer stem cells in different molecular subtypes of breast cancer[J];Chinese Journal of General Surgery;2011-11
3 HE Yu-qi1,LING Xian-long2,YU Jin-qiu1,LI Shi-wei2,ZHOU Yuan2,LI Xin-qiang2,YAN Bin2(1.Department of Internal Medicine,531 Hospital of People's Liberation Army,Tonghua 134002,China;2.Department of Gastroenterology,Xinqiao Hospital,Third Military Medical University,Chongqing 400037,China);Study on the relationship between mitochondrial DNA injury and multidrug resistance of human hepatocellular carcinoma[J];Tumor;2009-09
4 CHEN Ying-xin, LI Lian-hong, YANG Xiao-li, WANG Bo, WANG Li-xia (Center of China-Japan Clinical Pathology, Dalian Medical University, Dalian 116027, China);Expressions of CK5,CK8 and BCRP in the lesions of mammary gland and its significance[J];Tumor;2010-06
5 LOU Ying, SHEN Kun-wei (Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025,China);Prospect of breast cancer stem cells:from basic research to clinic application[J];Tumor;2010-06
6 HAN Yuzhen1,SANG Jing2,LU Zenghua3,ZHU Yuhong3 (1.Department of Pathological Sciences,Binzhou Medical University,Binzhou,Shandong 256603,China;2.Department of Pathology,the Central Hospital of Tai'an,Tai'an,Shandong 271000,China;3.Department of Pathology,the Affiliated Hospital,Binzhou Medical University,Binzhou,Shandong 256603,China);Clinicopathologic significance of breast cancer stem cells concerning their content and expression of drug resistance related proteins[J];Chinese Journal of General Surgery;2012-11
7 GENG Xuan 1 GENG Dan 2 JING Shi-bing 3 WANG Yan-qing 4 LIU Qing-feng 5 1.Second Clinical Medical College of Dalian Medical University,Dalian 116044,China;2.Department of Oncology,People's Hospital of Liaoning Province,Shenyang 110013,China;3.Department of Pathology,People 's Hospital of Liaoning Province,Shenyang 110013,China;4.Second Department of General Surgery,People's Hospital of Liaoning Province,Shenyang 110013,China;5.Department of Endocrine Surgery,People's Hospital of Liaoning Province,Shenyang 110013,China;Study of expression of ABCG2 in breast cancer and pericarcinomatous tissue and its clinical correlation[J];China Modern Medicine;2013-21
8 YANG Chao;CUI Zhichao;GUO Qingjun;LIU Yunjiang;WANG Shijie;Department of Breast Center,the Fourth Hospital,Hebei Medical University;Department of the First mammary,the People ’s Hospital of Tang Shan;Department of Educational Administration,Hebei Medical University;Department of Endoscope,the Fourth Hospital,Hebei Medical University;;The activity of special CTLs in diminishing CD55~(high) subgroup in human breast cancer MCF-7 cells[J];Chinese Journal of Cellular and Molecular Immunology;2013-11
【Co-references】
Chinese Journal Full-text Database 5 Hits
1 YUAN Jie,ZHU Xun,CHEN Sheng-ping.Key Laboratory of Tropical Disease Control(Sun Yat-sen University),Ministry of Education,Guangzhou 510080,China;A novel marine anthracycline D19 inhibits breast cancer cell MDA-MB-435 proliferation and cell cycle[J];South China Journal of Preventive Medicine;2010-06
2 Miao Yu-mei~1,Ma Ming-hui~2 (1 Zibo Mining Group Central Hospital,Zibo 255120,China;2 Zibo Municipal 5th People's Hospital,Zibo 255120,China);The Study of Cardiacβ-adrenergic Recepter Function in Acute Phase of Viral Myocarditis in Adult[J];Chinese Journal of Medicinal Guide;2011-04
3 Chen Dongmei (Department of Medicine,Nantong Tumor Hospital,Nantong 226361,China);A Clinical Observation of Gemcitabine and Capecitabine Combined Regimen in Advanced and Metastatic Breast Cancer Previously Treated with Anthracene Nucleus and Taxane Containing Regimens[J];Journal of Basic and Clinical Oncology;2009-05
4 LI Jun,XIAO Xiang-sheng(The 458th Hospital of PLA,Guangzhou,Guangdong 510602,China);Prospective Randomized Controlled Study of Cardiopretective Effect of Dexrazoxane on the Female Breast Cancer Patients with Postoperative Chemotherapy[J];Journal of Traditional Chinese Medicine University of Hunan;2012-02
5 WANG Zi-shu,WU Qiong,WANG Jun-bin,et al.Department of Medical Oncology,the First Affiliated Hospital of Bengbu Medical College,Bengbu 233004,Anhui,China;Recent Efficacy and Safety of Gemcitabine and Vinorelbine Combination Chemotherapy for Patients with Anthracycline and Taxane-Resistant Metastatic Breast Cancer[J];Chinese Journal of General Practice;2012-10
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved